Arcturus Therapeutics Holdings Inc ARCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ARCT is a good fit for your portfolio.
News
-
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
-
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
-
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
-
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
-
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
-
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
-
Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis
Trading Information
- Previous Close Price
- $26.32
- Day Range
- $25.57–26.88
- 52-Week Range
- $17.52–43.81
- Bid/Ask
- $25.00 / $26.00
- Market Cap
- $699.26 Mil
- Volume/Avg
- 625,391 / 496,831
Key Statistics
- Price/Earnings (Normalized)
- 10.05
- Price/Sales
- 4.44
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 180
- Website
- https://www.arcturusrx.com
Comparables
Valuation
|
Metric
|
ARCT
|
MRNA
|
SGMO
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.05 | 37.97 | — |
Price/Book Value | 2.54 | 2.81 | 1.04 |
Price/Sales | 4.44 | 5.77 | 0.48 |
Price/Cash Flow | — | — | — |
Price/Earnings
ARCT
MRNA
SGMO
Financial Strength
|
Metric
|
ARCT
|
MRNA
|
SGMO
|
|---|---|---|---|
Quick Ratio | 3.95 | 3.21 | 1.72 |
Current Ratio | 4.72 | 3.42 | 1.98 |
Interest Coverage | −57.99 | −113.82 | — |
Quick Ratio
ARCT
MRNA
SGMO
Profitability
|
Metric
|
ARCT
|
MRNA
|
SGMO
|
|---|---|---|---|
Return on Assets (Normalized) | −6.50% | −20.12% | −22.55% |
Return on Equity (Normalized) | −10.08% | −26.85% | −35.70% |
Return on Invested Capital (Normalized) | −12.53% | −26.68% | −34.64% |
Return on Assets
ARCT
MRNA
SGMO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Pfxvdhqbnc | Bjrp | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Ndgfmcyq | Jxbmm | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ghncbrd | Chrvyg | $98.1 Bil | |
MRNA
| Moderna Inc | Vrqypzl | Fcx | $39.1 Bil | |
ARGX
| argenx SE ADR | Krmdxnt | Cpb | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Nvkrxpks | Pzw | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bsxsmptpb | Hhntxd | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Yvmrpmph | Cnzgk | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mhgcrhklj | Gxrwnhw | $12.5 Bil | |
INCY
| Incyte Corp | Njppzfvbd | Fmxllk | $11.9 Bil |